Program
cariprazine
Also written as “Cariprazine”, “MP-214 3mg” and “MP-214 6mg”.
Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Bipolar Disorder · Mania · Depression, led by 7 companies.
Drug pageCariprazine: every studyMany companies study it; this page follows only the 41 they lead. All 53 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 291 open or running | phase 3since Jan 27, 2010 | Nov 27, 2006 | Mar 2027phase 3 · NCT04777357 |
| Tanabe Pharmaits history only | 60 open or running | phase 3since Jun 19, 2012 | Mar 15, 2009 | none ahead |
| Gedeon Richter Plc. | 21 open or running | phase 3since Jan 24, 2019 | Jun 13, 2014 | Dec 15, 2026phase 3 · NCT03817502 |
| Bostal Drug Deliveryits history only | 11 open or running | phase 3since Jul 15, 2026 | Jul 15, 2026 | Aug 2027phase 3 · NCT07722728 |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Jul 1, 2026 | Jul 1, 2026 | none ahead |
| Mapi Pharmaits history only | 11 open or running | phase 2since Aug 28, 2025 | Aug 28, 2025 | Dec 31, 2026phase 2 · NCT07185815 |
| Whanin Pharmaceuticalits history only | 10 open or running | phase 3since Nov 26, 2021 | Nov 26, 2021 | none ahead |
Also a collaborator on its studies: Gedeon Richter.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gedeon Richter Plc. only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 13, 2014First study: phase 1 study in Pharmacokinetic ProfileFirst studyNCT02165098 · 160 enrolled · United Kingdom
- Jan 24, 2019Phase 3 study in SchizophreniaNCT03817502 · 330 planned · United States, Bulgaria, Colombia and more
Ahead
- Dec 15, 2026Primary completion: phase 3 study in SchizophreniaNCT03817502
TargetBeta
“Dopamine D3 receptor modulator; Dopamine D2 receptor modulator”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| rotigotinerule | UCB | phase 4 | 64 |
| Pramipexolerule | Boehringer Ingelheim | phase 4 | 44 |
| ABBV-932 | AbbVie | phase 2 | 10 |
Studies
All 2 Gedeon Richter Plc. leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03817502Schizophrenia · United States, Bulgaria, Colombia and more | 3 | Recruiting | Dec 15, 2026 | 330 |
| NCT02165098Pharmacokinetic Profile · United Kingdom | 1 | Completed | Feb 2016 | 160 |
How it is read
Names in the registry
- “Cariprazine”, 25 entries
- “MP-214 3mg”, 3 entries
- “MP-214 6mg”, 3 entries
- “MP-214 9mg”, 3 entries
- “MP-214”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 21 studies
- Depressive Disorder, Major, 6 studies
- Bipolar Disorder, 6 studies
- Mania, 3 studies
- Depression, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.